• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals Inc (NQ: MIRM )

    39.15 +0.65 (+1.69%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 331,303
    Open 38.72
    Bid (Size) 35.47 (1)
    Ask (Size) 42.50 (1)
    Prev. Close 38.50
    Today's Range 38.24 - 39.98
    52wk Range 23.14 - 44.70
    Shares Outstanding 38,297,975
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +30.41%
    +30.41%
    1 Month
    +9.02%
    +9.02%
    3 Month
    +51.10%
    +51.10%
    6 Month
    +43.88%
    +43.88%
    1 Year
    +52.45%
    +52.45%

    More News

    Read More
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Analyst Ratings For Mirum Pharmaceuticals
    Via Benzinga
    Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
    Via Benzinga
    Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
    From Mirum Pharmaceuticals, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.